EyePoint (EYPT) Net Cash Flow (2010 - 2026)
EyePoint (EYPT) posted Net Cash Flow of -$24.1 million for Q1 2026, down 188.49% sequentially from $27.2 million in Q4 2025, and down 65.74% YoY from -$70.4 million in Q1 2025.
Analysis
EyePoint (EYPT) Net Cash Flow (2010 - 2026) Analysis & Trends
EyePoint has reported Net Cash Flow for 17 years, with the latest figure at -$24.1 million in Q1 2026.
- Quarterly Net Cash Flow fell 65.74% year-over-year to -$24.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.4 million (up 95.99% YoY) and the FY2025 annual result came in at $2.1 million, up 101.17% from the prior year.
- Net Cash Flow slipped to -$24.1 million in Q1 2026 per EYPT's latest filing, from $27.2 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $148.2 million in Q4 2023 and troughed at -$180.2 million in Q2 2024.
- A 5-year average of -$5.9 million and a median of -$6.8 million in 2022 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2023 and 2024: Net Cash Flow soared 631.23% in 2023, then sank 632.76% in 2024.
- Over 5 years, Net Cash Flow stood at $20.3 million in 2022, then jumped by 631.23% to $148.2 million in 2023, then plunged by 86.59% to $19.9 million in 2024, then soared by 37.08% to $27.2 million in 2025, then plunged by 188.49% to -$24.1 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$24.1 million, $27.2 million, and $3.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -183.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 374.50 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 407.41 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -496,000.00 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 225.59 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -37.14 Mn |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 | 32.75 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 32.75 Mn |
| Mar 31, 2026 | -24.11 Mn |
| Dec 31, 2025 | 27.24 Mn |
| Sep 30, 2025 | 3.43 Mn |
| Jun 30, 2025 | -14.02 Mn |
| Mar 31, 2025 | -14.55 Mn |
| Dec 31, 2024 | 19.87 Mn |
| Sep 30, 2024 | -10.94 Mn |
| Jun 30, 2024 | -180.24 Mn |
| Mar 31, 2024 | -10.25 Mn |
| Dec 31, 2023 | 148.23 Mn |
| Sep 30, 2023 | -6.56 Mn |
| Jun 30, 2023 | 33.83 Mn |
| Mar 31, 2023 | 10.13 Mn |
| Dec 31, 2022 | 20.27 Mn |
| Sep 30, 2022 | -6.77 Mn |
| Jun 30, 2022 | -19.41 Mn |
| Mar 31, 2022 | -77.05 Mn |
| Dec 31, 2021 | 58.88 Mn |
| Sep 30, 2021 | -7.92 Mn |